scroll down

About Us

Founded in 2019, Zenitar is a late-stage clinical biotechnology company focused on developing highly differentiated small-molecule therapies with FIC or BIC potential. Leveraging three integrated R&D platforms – structural biology, AI-powered drug design, and clinically relevant disease models – we aim to address major unmet medical needs across Hem/Onc, CNS, and I&I. Our pipeline spans clinical and preclinical programs, with two lead assets currently in Phase 3 registrational development, alongside multiple programs advancing toward global clinical development.

  • 2019

    Founded

  • 60+

    R&D Personnel

  • 70+

    Granted Patents

Learn more >> Learn more >>

  • 01

    Structural Biology Platform

    Structural Biology Platform

    Zenitar's structural biology platform efficiently utilizes X-ray crystallography and cryo-EM to analyze protein-drug complex structures for pipeline targets.

    Learn more >> Learn more >>

  • 02

    AI-Driven Drug Design Platform

    AI-Driven Drug Design Platform

    Zenitar's AI-driven platform, AlloMol.AI, supports target identification, binding site prediction, molecular design, and druggability assessment, greatly boosting the efficiency of our internal pipeline development.

    Learn more >> Learn more >>

  • 03

    In Vitro Drug Screening Model

    In Vitro Drug Screening Model

    Zenitar's in vitro drug screening platform is designed to address unmet clinical needs.

    Learn more >> Learn more >>

  • 04

    In Vivo Drug Efficacy Screening Platform

    In Vivo Drug Efficacy Screening Platform

    Zenitar's in vivo efficacy platform provides a robust and clinically relevant tool for cancer research and drug development.

    Learn more >> Learn more >>

Our Portfolio